What's Happening?
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced new data from an open-label extension study of repinatrabit, a treatment for phenylketonuria (PKU). The study, presented at the 2026 American
College of Medical Genetics and Genomics meeting, showed significant reductions in blood phenylalanine levels in adolescents. The study is part of a broader effort to develop repinatrabit for a wide range of PKU patients, including adults. The drug, a selective small-molecule inhibitor, demonstrated a 67% mean reduction in blood Phe levels from baseline in adolescents. The ongoing pivotal Phase 3 PheORD trial aims to further evaluate the drug's efficacy and safety in adults.
Why It's Important?
The development of repinatrabit is significant for the PKU community, as maintaining control of blood Phe levels is a major challenge, particularly for adolescents. High Phe levels can lead to cognitive impairments and other health issues. Repinatrabit offers a novel approach to treatment, potentially broadening options for patients who have limited alternatives. The drug's progress through clinical trials could lead to a new standard of care for PKU, impacting thousands of individuals in the U.S. and globally. The study's results also reinforce the potential of repinatrabit across different age groups, which could lead to its approval and availability for a broader patient population.
What's Next?
The pivotal Phase 3 PheORD trial is currently underway, with completion of the primary endpoint expected in late 2026 and full study completion by 2028. This trial will assess the efficacy and safety of repinatrabit in adults with PKU, using a randomized, double-blind, placebo-controlled design. The trial's outcomes will be crucial for regulatory approval and potential market introduction. Otsuka is actively recruiting participants, reflecting real-world clinical practice by including a broad range of disease severities and prior treatment experiences. The results of this trial will determine the next steps in the drug's development and potential commercialization.
